BioXcel Therapeutics (BTAI) Long-Term Debt Issuances (2022)

BioXcel Therapeutics (BTAI) recorded quarterly Long-Term Debt Issuances of $30.0 million in Q3 2022.

BioXcel Therapeutics (BTAI) Long-Term Debt Issuances (2022) Analysis & Trends

BioXcel Therapeutics' Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $30.0 million for Q3 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn -
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 1.51 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn -
10 BioXcel Therapeutics 25.46 Mn 25.46 Mn -77,000.00 -

Historic Data

Download Data
DateValue
Sep 30, 2022 30.00 Mn
Sep 30, 2022 30.00 Mn